|
|
|
|
| LEADER |
03650nam a2200421 u 4500 |
| 001 |
EB001874852 |
| 003 |
EBX01000000000000001038219 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
191026 r ||| eng |
| 020 |
|
|
|a 9788281214149
|
| 100 |
1 |
|
|a Ringerike, Tove
|
| 245 |
0 |
0 |
|a Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip or knee replacement surgery
|h Elektronische Ressource
|c Ringerike, Tove, Hamidi, Vida, Hagen, Gunhild, Reikvam, Åsmund, Klemp, Marianne
|
| 246 |
3 |
1 |
|a Tromboseprofylakse ved hofte og kneprotesekirurgi
|
| 260 |
|
|
|a Oslo
|b Norwegian Knowledge Centre for the Health Services
|c June 2011, 2011
|
| 300 |
|
|
|a 1 PDF file (92 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Heparin
|
| 653 |
|
|
|a Arthroplasty, Replacement, Hip / adverse effects
|
| 653 |
|
|
|a Pulmonary Embolism / drug therapy
|
| 653 |
|
|
|a Technology Assessment, Biomedical
|
| 653 |
|
|
|a Arthroplasty, Replacement, Knee / adverse effects
|
| 653 |
|
|
|a Pulmonary Embolism / prevention & control
|
| 653 |
|
|
|a Thromboembolism / prevention & control
|
| 653 |
|
|
|a Antithrombins
|
| 653 |
|
|
|a Thromboembolism / drug therapy
|
| 700 |
1 |
|
|a Hamidi, Vida
|e [author]
|
| 700 |
1 |
|
|a Hagen, Gunhild
|e [author]
|
| 700 |
1 |
|
|a Reikvam, Åsmund
|e [author]
|
| 710 |
2 |
|
|a Nasjonalt kunnskapssenter for helsetjenesten
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Report from Kunnskapssenteret
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK390593
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 600
|
| 520 |
|
|
|a Due to a high risk of thromboembolism in patients undergoing major orthopaedic surgery it has become standard practice to give thromboprophylactic treatment to these patients. Pharmaceutical interventions with or without addition of mechanical methods are recommended. This project, commissioned by Helse Bergen HF Ortopedisk klinikk, examined thromboprophylaxis with rivaroxaban or dabigatran compared with low-molecular weight heparins (LMWH, i.e. enoxaparin and dalteparin) with regard to efficacy, safety and cost-effectiveness in patients undergoing elective total hip or knee replacement surgery. We conducted a systematic review of the literature and made cost-effectiveness analyses based on a model that calculated quality-adjusted life years and life time costs. The main findings were that:1. We did not find statistically significant differences between dabigatran and enoxaparin for mortality, pulmonary embolism, deep vein thrombosis or major bleeding. The quality of the evidence ranged from very low to moderate.2. For rivaroxaban compared with enoxaparin we found statistically a significant reduction in deep vein thrombosis, but also a trend towards increased risk of major bleeding. For mortality and pulmonary embolism there were no statistically significant differences between treatments. The quality of the evidence ranged from very low to moderate.3. Our results indicate a great uncertainty regarding which strategy is the most cost-effective. However, rivaroxaban and enoxaparin had a slightly higher probability of being cost-effective alternatives for patients undergoing total hip or knee replacement, respectively.4. The results of our model analysis of the uncertainty surrounding each group of parameters indicated that more research on efficacy data would have the greatest impact on reducing decision uncertainty
|